End-of-day quote
Shenzhen S.E.
06:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
20.79
CNY
|
+1.81%
|
|
+6.13%
|
-9.49%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
2,938
|
2,411
|
4,350
|
7,761
|
8,945
|
Enterprise Value (EV)
1 |
2,516
|
2,041
|
3,622
|
5,915
|
4,640
|
P/E ratio
|
40.8
x
|
58.4
x
|
9.03
x
|
4.99
x
|
2.1
x
|
Yield
|
1.59%
|
0.28%
|
3.17%
|
6.08%
|
9.08%
|
Capitalization / Revenue
|
16.7
x
|
13.3
x
|
4.54
x
|
2.74
x
|
0.85
x
|
EV / Revenue
|
14.3
x
|
11.3
x
|
3.78
x
|
2.09
x
|
0.44
x
|
EV / EBITDA
|
36.6
x
|
42
x
|
6.45
x
|
3.47
x
|
0.9
x
|
EV / FCF
|
-81.7
x
|
-149
x
|
14
x
|
9.36
x
|
1.79
x
|
FCF Yield
|
-1.22%
|
-0.67%
|
7.17%
|
10.7%
|
55.8%
|
Price to Book
|
4.99
x
|
3.95
x
|
3.95
x
|
2.78
x
|
1.38
x
|
Nbr of stocks (in thousands)
|
206,956
|
206,956
|
214,478
|
232,840
|
232,728
|
Reference price
2 |
14.19
|
11.65
|
20.28
|
33.33
|
38.44
|
Announcement Date
|
4/24/19
|
4/29/20
|
5/14/21
|
4/26/22
|
4/20/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
165.1
|
176.4
|
181.2
|
959.1
|
2,830
|
10,530
|
EBITDA
1 |
77.82
|
68.66
|
48.63
|
561.8
|
1,704
|
5,180
|
EBIT
1 |
68.26
|
55.51
|
31.86
|
544.6
|
1,683
|
5,135
|
Operating Margin
|
41.34%
|
31.47%
|
17.59%
|
56.78%
|
59.47%
|
48.77%
|
Earnings before Tax (EBT)
1 |
75.43
|
70.83
|
46.55
|
556.7
|
1,695
|
5,076
|
Net income
1 |
65.49
|
61.42
|
41.53
|
468.9
|
1,413
|
4,208
|
Net margin
|
39.66%
|
34.82%
|
22.92%
|
48.89%
|
49.94%
|
39.97%
|
EPS
2 |
0.4215
|
0.3475
|
0.1995
|
2.246
|
6.675
|
18.31
|
Free Cash Flow
1 |
-18.47
|
-30.81
|
-13.74
|
259.6
|
631.6
|
2,590
|
FCF margin
|
-11.19%
|
-17.47%
|
-7.58%
|
27.07%
|
22.32%
|
24.59%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
46.21%
|
37.07%
|
49.99%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
55.36%
|
44.7%
|
61.54%
|
Dividend per Share
|
-
|
0.2252
|
0.0322
|
0.6435
|
2.027
|
3.490
|
Announcement Date
|
5/26/18
|
4/24/19
|
4/29/20
|
5/14/21
|
4/26/22
|
4/20/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
125
|
422
|
371
|
728
|
1,846
|
4,305
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-18.5
|
-30.8
|
-13.7
|
260
|
632
|
2,590
|
ROE (net income / shareholders' equity)
|
31.4%
|
15%
|
7.04%
|
55%
|
73%
|
91.1%
|
ROA (Net income/ Total Assets)
|
18.8%
|
7.94%
|
3.17%
|
33%
|
43.4%
|
50.9%
|
Assets
1 |
348.2
|
773.4
|
1,309
|
1,423
|
3,254
|
8,266
|
Book Value Per Share
2 |
1.550
|
2.840
|
2.950
|
5.140
|
12.00
|
27.90
|
Cash Flow per Share
2 |
0.8000
|
1.290
|
0.8200
|
3.120
|
5.110
|
11.00
|
Capex
1 |
45.5
|
47.5
|
31.9
|
28.3
|
104
|
313
|
Capex / Sales
|
27.57%
|
26.92%
|
17.63%
|
2.95%
|
3.66%
|
2.98%
|
Announcement Date
|
5/26/18
|
4/24/19
|
4/29/20
|
5/14/21
|
4/26/22
|
4/20/23
|
|
1st Jan change
|
Capi.
|
---|
| -9.49% | 668M | | -1.89% | 12.56B | | -9.59% | 7.68B | | +21.82% | 5.18B | | -1.31% | 5.29B | | +0.02% | 4.57B | | -50.89% | 3.29B | | +6.42% | 2.6B | | -10.02% | 2.2B | | -8.29% | 1.79B |
Diagnostic & Testing Substances
|